CN101951912A - 创伤后应激障碍的治疗 - Google Patents

创伤后应激障碍的治疗 Download PDF

Info

Publication number
CN101951912A
CN101951912A CN200880108123XA CN200880108123A CN101951912A CN 101951912 A CN101951912 A CN 101951912A CN 200880108123X A CN200880108123X A CN 200880108123XA CN 200880108123 A CN200880108123 A CN 200880108123A CN 101951912 A CN101951912 A CN 101951912A
Authority
CN
China
Prior art keywords
nepicastat
patient
dopamine
compound
post
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880108123XA
Other languages
English (en)
Chinese (zh)
Inventor
T·沃伊沃德
M·莫兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Department Of Biology Therapeutics Inc
Original Assignee
Synosia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synosia Therapeutics Inc filed Critical Synosia Therapeutics Inc
Publication of CN101951912A publication Critical patent/CN101951912A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN200880108123XA 2007-07-23 2008-07-23 创伤后应激障碍的治疗 Pending CN101951912A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93503607P 2007-07-23 2007-07-23
US60/935036 2007-07-23
PCT/US2008/070948 WO2009015248A1 (en) 2007-07-23 2008-07-23 Treatment of post-traumatic stress disorder

Publications (1)

Publication Number Publication Date
CN101951912A true CN101951912A (zh) 2011-01-19

Family

ID=40281815

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880108123XA Pending CN101951912A (zh) 2007-07-23 2008-07-23 创伤后应激障碍的治疗

Country Status (12)

Country Link
US (1) US20090054403A1 (https=)
EP (1) EP2182952A4 (https=)
JP (1) JP2010534676A (https=)
CN (1) CN101951912A (https=)
AU (1) AU2008279091A1 (https=)
CA (1) CA2707858A1 (https=)
CO (1) CO6260078A2 (https=)
MX (1) MX2010000937A (https=)
NZ (1) NZ583193A (https=)
RU (1) RU2458691C2 (https=)
SG (1) SG183069A1 (https=)
WO (1) WO2009015248A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109966281A (zh) * 2019-04-11 2019-07-05 北京大学 PAO作为Pi4KIIα抑制剂在制备治疗创伤后应激障碍药物中的应用
CN110996987A (zh) * 2017-05-30 2020-04-10 保罗·G·爱默生 用于调控应激障碍中激素级联的组合物和方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008279169A1 (en) * 2007-07-23 2009-01-29 Biotie Therapies, Inc 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder
EP3251670A1 (en) * 2007-08-06 2017-12-06 Biotie Therapies, Inc. Methods for treating dependence
AU2016208412A1 (en) * 2007-08-06 2016-08-18 Biotie Therapies, Inc. Methods for treating dependence
SMT201700578T1 (it) * 2009-11-20 2018-01-11 Tonix Pharma Holdings Ltd Metodo e composizioni per trattare i sintomi associati al disturbo da stress post-traumatico usando ciclobenzaprina
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
SMT202400324T1 (it) 2013-03-15 2024-11-15 Tonix Pharma Ltd Formulazioni eutettiche di ciclobenzaprina cloridrato e mannitolo
AU2014354808A1 (en) * 2013-11-26 2016-06-02 University Of North Texas Health Science Center At Fort Worth Personalized medicine approach for treating cognitive loss
MY186047A (en) 2014-09-18 2021-06-17 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
RU2614697C1 (ru) * 2016-04-12 2017-03-28 Общество с ограниченной ответственностью "Нормофарм" Нейропротекторное средство
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
AU2018204843B2 (en) * 2017-07-05 2023-07-27 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating anxiety disorders in patients via renal neuromodulation
EP3720856A1 (en) 2017-12-04 2020-10-14 BIAL - PORTELA & Cª, S.A. Dopamine-& x392;-hydroxylase inhibitors
MX2020006140A (es) 2017-12-11 2020-08-13 Tonix Pharma Holdings Ltd Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas.
US12521362B2 (en) * 2019-07-25 2026-01-13 Tokyo University Of Science Foundation Agent for treating, preventing, or improving psychiatric and nervous system disorders or symptoms
CN120882371A (zh) * 2022-11-30 2025-10-31 闪烁实验室有限公司 使用眼睑跟踪的精神药理学系统和方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
CA2459304A1 (en) * 2001-09-13 2003-03-20 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
EP1336406A1 (en) * 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
WO2005079756A2 (en) * 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
WO2006096434A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
JP2009500421A (ja) * 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及び抗うつ薬の組み合わせ
WO2008115706A1 (en) * 2007-03-16 2008-09-25 Emory University Methods and compositions for treatment of drug addiction
WO2009015244A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics Rufinamide for the treatment of post-traumatic stress disorder

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110996987A (zh) * 2017-05-30 2020-04-10 保罗·G·爱默生 用于调控应激障碍中激素级联的组合物和方法
CN109966281A (zh) * 2019-04-11 2019-07-05 北京大学 PAO作为Pi4KIIα抑制剂在制备治疗创伤后应激障碍药物中的应用
CN109966281B (zh) * 2019-04-11 2021-04-27 北京大学 PAO作为Pi4KIIα抑制剂在制备治疗创伤后应激障碍药物中的应用

Also Published As

Publication number Publication date
EP2182952A1 (en) 2010-05-12
AU2008279091A1 (en) 2009-01-29
SG183069A1 (en) 2012-08-30
EP2182952A4 (en) 2010-09-08
CO6260078A2 (es) 2011-03-22
JP2010534676A (ja) 2010-11-11
NZ583193A (en) 2012-05-25
CA2707858A1 (en) 2009-01-29
US20090054403A1 (en) 2009-02-26
WO2009015248A1 (en) 2009-01-29
RU2010106014A (ru) 2011-08-27
MX2010000937A (es) 2010-06-25
RU2458691C2 (ru) 2012-08-20

Similar Documents

Publication Publication Date Title
CN101951912A (zh) 创伤后应激障碍的治疗
US20200383951A1 (en) Methods for treating dependence
Burnette et al. Novel agents for the pharmacological treatment of alcohol use disorder
US20230382885A1 (en) Enantiomeric entactogen compositions and their use
US12404257B2 (en) Advantageous benzofuran compositions for mental disorders or enhancement
US20230183199A1 (en) 2-aminoindane compounds for mental disorders or enhancement
WO2010124089A2 (en) Methods for treating dependence
AU2018203524B2 (en) Methods for treating dependence
CA3146837A1 (en) Compound for combination treatment
AU2014202047A1 (en) Methods for treating dependence
HK1155063A (en) Treatment of post-traumatic stress disorder
HK1241721A1 (en) Methods for treating dependence
HK1143038A (en) Methods for treating dependence
Konofal et al. Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic Potential: E. Konofal et al.
STEINHEYER et al. Basic and Clinical Aspects of Depression

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1155063

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: BIOLOGY THERAPY COMPANY

Free format text: FORMER OWNER: SYNOSIA THERAPEUTICS, INC.

Effective date: 20121213

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20121213

Address after: American California

Applicant after: Department of biology therapeutics Inc

Address before: American California

Applicant before: Synosia Therapeutics

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110119

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1155063

Country of ref document: HK